Effectiveness of ACE Inhibitors and ARBs in Heart Failure Management
Dosing Considerations for ACE Inhibitors and ARBs
- The American College of Cardiology recommends that ACE inhibitors and ARBs be titrated to maximally tolerated doses to reduce morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF) 1
- Achieving at least 50% of the target total daily dose is a key performance measure for ACE inhibitors and ARBs, with the total daily dose being more important than the dosing frequency 1
- Several ACE inhibitors, including captopril, enalapril, and quinapril, are designed for twice-daily administration in their standard dosing regimens 3
Target Doses and Flexibility in Administration
- The American College of Cardiology and American Heart Association (ACC/AHA) guidelines specify that the minimum effective dose is considered to be 50% of the target dose for both ACE inhibitors and ARBs 1
- For example, enalapril's target dose is 10 mg twice daily (20 mg total), with 10 mg daily (50% of target) considered clinically effective 1, 3
- Valsartan's target dose is 160 mg twice daily (320 mg total), with 160 mg daily (50% of target) still providing clinical benefit 1, 3
Clinical Implications and Recommendations
Benefits of Split Dosing
- For patients with low blood pressure, starting with lower doses and gradually titrating up with small increments is recommended, which may include twice-daily administration of smaller doses 4
- The 2022 AHA/ACC/HFSA guidelines emphasize that clinical trials of ACE inhibitors, ARBs, and other heart failure medications typically initiated therapy at low doses and gradually titrated to target doses, regardless of symptomatic improvement at lower doses 2
Practical Application
- When initiating ACE inhibitors or ARBs, start with low doses and gradually increase to target doses while monitoring for adverse effects 3, 5
- For patients who cannot tolerate once-daily target doses, splitting into twice-daily administration of lower doses is a reasonable approach to achieve the total daily target dose 1, 3
- Monitor renal function and serum potassium within 1-2 weeks of initiation and periodically thereafter, especially in high-risk patients 3, 5
Special Populations and Considerations
Elderly and Frail Patients
- The International Society of Hypertension guidelines recommend simplifying regimens with once-daily dosing when possible, but acknowledge that dose adjustments may be needed in elderly or frail patients 6, 7, 8
- In patients aged >80 years or who are frail, starting with lower doses and potentially using split dosing may improve tolerability 9